MedTrace Logo

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

NCT06674135 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2024-11-07

No results posted yet for this study

Summary

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh

Conditions

  • Type I Diabetes

Interventions

DRUG

biosimilar insulin glargine

Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe

Sponsors & Collaborators

  • Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

    collaborator OTHER

  • BADAS-Centre for Health Research and Implementation

    collaborator UNKNOWN

  • Diabetic Association of Bangladesh (BADAS)

    collaborator UNKNOWN

  • Life for a Child Program, Diabetes Australia

    lead OTHER

Principal Investigators

  • Dr Bedowra Zabeen, MBBS, FCPS(Paediatrics), FRSPH · Life For a Child Program, BIRDEM, BADAS, Bangladesh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-08-31
Completion
2023-08-31
FDA Drug
Yes

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06674135 on ClinicalTrials.gov